Hints and tips:
Related Special Reports
...“We have made tremendous progress in strengthening the financial position of the company,” it added....
...The windfall from Covid vaccines gives the company the money to back research for many jabs. But investors have also been nervous about how much the company has been spending....
...It’s moving into the customisation phase which would spread some of this [trading] out,” Armour said....
...Shah Capital now owns 6.7 per cent of Novavax, having first bought into the company in the last quarter of 2022....
...Any rumours that the company is at risk of defaulting are “flatly untrue”, he said....
...Shockwave’s technology has treated approximately 400,000 patients globally, the company said....
...“Despite a strong stock market, investors have focused on higher quality ETFs that own companies with strong balance sheets and consistent earnings and cash flow,” he said, pointing to robust flows into...
...Illumina said the company agreed “with the advocate general that the European Commission’s assertion of jurisdiction over this merger was improper”. Illumina bought Grail in 2021....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded....
...In response, Armour said, State Street dropped its fee to 5 bps and then Schwab slashed its fee to 3 bps in late September....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...But Armour said buying these ETFs shared little in common with buying into a private equity fund....
...In the past decade, the company rolled out four BlackRock-branded fixed income SMAs and four equity SMAs, according to data from the company’s website....
...Leveraged ETFs have a negative combined rate of return over the past decade, Armour said....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...“be everything to everyone”, Vanguard’s ETF suite “takes a different take” by focusing only on stocks and bonds while leveraging the group’s reputation for low-cost, broad-based strategies, said Bryan Armour...
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Packaged food companies have built strong and trusted brands over decades....
...The Cypriot government allowed stocks to be used to treat cats suffering with another coronavirus in the Mediterranean country, though the company said it was not approved for veterinary treatment and no...
...The UK pharmaceutical retailer’s transfer of £4.8bn of pension obligations to insurer Legal & General brings its potential sale by owner Walgreens Boots Alliance one step closer....
...Large pharmaceutical companies are increasingly interested in immunology — tackling diseases often caused by an overactive immune system — because of the large number of affected patients....
International Edition